VMI
MRSN

VHCP Management II’s Mersana Therapeutics MRSN Stock Holding History

VHCP Management II’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$5.29M Buy
+36,901
New +$2.7M 1.39% 9

Other funds holding MRSN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

VHCP Management II's MRSN Position: Q4 2019 in Review

VHCP Management II opened a new position in Mersana Therapeutics (MRSN) in Q4 2019: 36,901 shares worth $5.29M. The stake represents 1.39% of the portfolio and ranks #9 among its holdings.

69 funds tracked by Wall St. Rank hold MRSN as of Q4 2019.

  • VHCP Management II held 36,901 shares of Mersana Therapeutics worth $5.29M as of Q4 2019.
  • Mersana Therapeutics was a new VHCP Management II position in Q4 2019.
  • Mersana Therapeutics made up 1.39% of VHCP Management II's portfolio in Q4 2019, its #9 holding.
  • 69 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2019.

Based on VHCP Management II's 13F filing for Q4 2019, filed 13 Feb 2020.